La scRNA-Seq rivela le risposte immunitarie anti-linfoma nelle eruzioni cutanee associate a mogamulizumab.

BACKGROUND: Mogamulizumab is an anti-CCR4 therapeutic antibody approved for relapsed or refractory mycosis fungoides, Sézary syndrome and adult T-cell leukaemia/lymphoma. During treatment, a subset of patients develops a mogamulizumab-associated drug rash (MAR) that is associated with a better overall survival, but underlying mechanisms remain unclear. In addition, misinterpretation of MAR as cutaneous T-cell lymphoma (CTCL) progression can lead to unnecessary drug discontinuation. OBJECTIVES: To conduct a comprehensive molecular characterization of MAR. METHODS: We performed single-cell RNA sequencing of skin biopsies from 4 patients with MAR, compared to untreated erythrodermic CTCL (CTC